Delays in last sale prices can result in missed opportunities and lost profits. In the stock market, timing is everything.

See How Commodities are Trading Today

.
Intel

90 Second Review: 2015 Outlook for Biotech .

Foreseeable Boost for Biotechnology

90 Second Review: 2015 Outlook for Biotech

Foreseeable Boost for Biotechnology

This week's Nasdaq Corporate Solutions Advisory Services commentary features Joe Rosenberg, healthcare and biotechnology specialist, delivering his outlook for the biotechnology sector in 2015:

  • Accommodating regulatory environment - the FDA approved 41 new drugs during 2014, the largest number of yearly approvals in at least a decade.
  • 2015 promises to be a big year for M&A - companies will seek to expand their portfolios of marketed drugs, grow their R&D pipelines, and complement existing businesses.
TAGS: Market Data
Scroll up